To date, in clinical practice, only the anti-IL-31 RA antibody nemolizumab reached phase III of the clinical trial in patients with atopic dermatitis, which, combined with topical agents, resulted in a greater reduction in pruritus [29]. This evidence concerns the gene IL31 and atopic eczema.